BamSEC and AlphaSense Join Forces
Learn More

Enanta Pharmaceuticals Inc. – Material Contracts

NASDAQ: ENTA    
Share price (9/4/26): $14.08    
Market cap (9/4/26): $410 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 12 pages Enanta Pharmaceuticals, Inc. 2019 Equity Incentive Plan
12/34/56
EX-10.1
from 10-Q 4 pages Enanta Pharmaceuticals, Inc. Incentive Stock Option Grant Notice and Option Agreement
12/34/56
EX-10.1
from 8-K 12 pages Enanta Pharmaceuticals, Inc. 2019 Equity Incentive Plan
12/34/56
EX-10.2
from 10-Q 11 pages Enanta Pharmaceuticals, Inc. 2024 Inducement Stock Incentive Plan
12/34/56
EX-10.1
from 10-Q 12 pages Enanta Pharmaceuticals, Inc. 2019 Equity Incentive Plan
12/34/56
EX-10.31
from 10-K 4 pages Third Amendment to Lease Agreement
12/34/56
EX-10.30
from 10-K 5 pages Second Amendment to Lease Agreement
12/34/56
EX-10.29
from 10-K 6 pages Enanta Pharmaceuticals, Inc. 2024 Inducement Stock Incentive Plan Relative Total Stockholder Return Unit Certificate
12/34/56
EX-10.28
from 10-K 4 pages Enanta Pharmaceuticals, Inc. 2024 Inducement Stock Incentive Plan Performance Share Unit Certificate
12/34/56
EX-10.27
from 10-K 4 pages Enanta Pharmaceuticals, Inc. Restricted Stock Unit Grant Notice and Award Agreement
12/34/56
EX-10.26
from 10-K 4 pages Enanta Pharmaceuticals, Inc. Nonstatutory Stock Option Grant Notice and Agreement
12/34/56
EX-10.2
from 10-Q 5 pages Amended and Restated Employment Agreement
12/34/56
EX-10.1
from 8-K 12 pages Enanta Pharmaceuticals, Inc. 2019 Equity Incentive Plan
12/34/56
EX-10.1
from 8-K 50 pages Certain Identified Information Has Been Omitted From This Exhibit Because It Is (I) Not Material and (II) of the Type That the Registrant Treats as Private or Confidential. [***] Indicates That Information Has Been Omitted. Royalty Purchase Agreement Between Enanta Pharmaceuticals, Inc. and Ocm Life Sciences Portfolio LP Dated as of April 25, 2023
12/34/56
EX-10
from 8-K 14 pages Enanta Pharmaceuticals, Inc. 2019 Equity Incentive Plan
12/34/56
EX-10.3
from 8-K 93 pages Lease Agreement
12/34/56
EX-10.2
from 8-K 34 pages First Amendment to Lease Agreement
12/34/56
EX-10.1
from 8-K 4 pages Second Amendment to Lease
12/34/56
EX-10.1
from 10-Q 9 pages Consulting Agreement
12/34/56
EX-10.1
from 8-K 12 pages Enanta Pharmaceuticals, Inc. 2019 Equity Incentive Plan
12/34/56